-
Product Insights
NewApolipoprotein A I – Drugs In Development, 2024
The Apolipoprotein A I pipeline drugs market research report outlays comprehensive information on the Apolipoprotein A I targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Metabolic Disorders, Genito Urinary System, and Ophthalmology which include indications of Atherosclerosis, Acute Coronary Syndrome, Hypercholesterolemia, Lecithin-Cholesterol Acyltransferase (LCAT) Deficiency, Kidney Disease (Nephropathy), and Uveitis. It also reviews key players involved...
-
Product Insights
NewComplement Factor I – Drugs In Development, 2024
The Complement Factor I pipeline drugs market research report outlays comprehensive information on the Complement Factor I targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology which include indications of Geographic Atrophy, and Dry (Atrophic) Macular Degeneration. It also reviews key players involved in Complement Factor I targeted therapeutics development with respective active and dormant or discontinued...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MTL-CEBPA in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MTL-CEBPA in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MTL-CEBPA in Mucopolysaccharidosis I (MPS I)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lepunafusp Alfa in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lepunafusp Alfa in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lepunafusp Alfa in Mucopolysaccharidosis I...
-
Product Insights
NewBuzios ECO I Field, Brazil
Empower your strategies with our Buzios ECO I Field, Brazil report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain a gateway to actionable insights and competitive advantage. Acquire a thorough understanding of...
-
Product Insights
NewSapugaskanda I Refinery, Sri Lanka
Empower your strategies with our Sapugaskanda I Refinery, Sri Lanka report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain a gateway to actionable insights and competitive advantage. Acquire a thorough understanding of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pentosan Polysulfate Sodium in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pentosan Polysulfate Sodium in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pentosan Polysulfate Sodium in...
-
Product Insights
NewNet Present Value Model: I-Mab’s Felzartamab
Empower your strategies with our Net Present Value Model: I-Mab's Felzartamab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: I-Mab’s Uliledlimab
Empower your strategies with our Net Present Value Model: I-Mab's Uliledlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: I-Mab’s Lemzoparlimab
Empower your strategies with our Net Present Value Model: I-Mab's Lemzoparlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.